Vorinostat Completed Phase 1 Trials for Childhood Central Nervous System Teratoma / Recurrent Childhood Cerebellar Astrocytoma / Childhood Low-grade Cerebral Astrocytoma / Childhood Infratentorial Ependymoma / Recurrent Childhood Medulloblastoma / Childhood Grade II Meningioma / Childhood Supratentorial Ependymoma / Recurrent Childhood Central Nervous System Embryonal Tumor / Childhood Mixed Glioma / Childhood High-grade Cerebral Astrocytoma / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Extra-Adrenal Paraganglioma / Childhood Craniopharyngioma / Childhood Central Nervous System Embryonal Tumor / Childhood High-grade Cerebellar Astrocytoma / Recurrent Childhood Spinal Cord Neoplasm / Childhood Grade III Meningioma / Childhood Choroid Plexus Tumor / Childhood Central Nervous System Choriocarcinoma / Recurrent Childhood Cerebral Astrocytoma / Childhood Medulloepithelioma / Childhood Grade I Meningioma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Childhood Oligodendroglioma / Childhood Ependymoblastoma / Childhood Atypical Teratoid/Rhabdoid Tumor / Recurrent Childhood Ependymoma / Childhood Central Nervous System Yolk Sac Tumor / Recurrent Childhood Brain Stem Glioma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Germinoma / Childhood Low-grade Cerebellar Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01076530Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors